Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

AI-powered treatment allocation improves public health outcomes

A new study sheds light on a promising approach using machine learning to more effectively allocate medical treatments during a pandemic or any time there's a shortage of therapeutics.

14 Sep 2024

Current and emerging biomarkers in the management of inflammatory bowel disease

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal (GI) tract that significantly impacts the quality of life of patients.

12 Sep 2024

Study links protein increases to cognitive improvement in Alzheimer's

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.

11 Sep 2024

Novel monoclonal antibody appears effective at neutralizing numerous SARS-CoV-2 variants

A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a threat if they were to begin spreading in people.

6 Sep 2024

Fibrin fuels thromboinflammation and brain damage in COVID-19

Researchers reveal fibrin's critical role in COVID-19 by driving thromboinflammation and neuropathology, and highlight a potential antibody therapy to mitigate these effects.

29 Aug 2024

Study reveals the role of blood clotting in COVID-19

In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that have become hallmarks of the disease, while also suppressing the body's ability to clear the virus.

29 Aug 2024

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

Exploring alemtuzumab in reduced-toxicity conditioning for Asian patients with inborn errors of immunity

Allogeneic hematopoietic cell transplantation (HCT) is a commonly used curative therapy for individuals with inborn errors of immunity (IEI).

28 Jul 2024

Breakthrough research identifies fibrin as key factor in preterm brain bleeds

Mark Petersen, MD, has seen firsthand the devastating effects of brain bleeds in premature babies. It's an exceedingly common condition that affects up to 20 percent of infants born before 28 weeks of gestation, bringing an increased risk for developmental delays and autism.

24 Jul 2024

Researchers identify ORF6 protein as key to SARS-CoV-2 immune evasion

An article published in the journal Cell describes a study that enabled a group of researchers to discover how SARS-CoV-2 evades the cytotoxic immune response by identifying a protein called ORF6 that is a key factor in this mechanism.

16 Jul 2024

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

Emerging personalized treatment approaches for chronic urticari.

16 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

Clinical trial seeks to evaluate safety of new EV-D68 treatment

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM) – similar to polio. Scientists are striving to better understand AFM, which has emerged in the United States with spikes in cases every other year, primarily in the late-summer months over the last decade.

28 Jun 2024

Beckman Coulter Life Sciences Releases Innovative Assay to Quantify Antibody Aggregation

...

From Beckman Coulter Life Sciences - Flow Cytometry 5 Jun 2024

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

Applied Cells releases game-changing reagent kits to empower cell therapy development

Applied Cells is excited to announce the launch of its MARS® Ingenuity™ Reagent kits for fast and easy cell isolation. This innovative product line features both RUO and GMP-grade reagents, and has been specifically optimized for use on Applied Cells’ proprietary MARS® Bar platform.

From Applied Cells 4 Jun 2024

New antibody shows promise as universal weapon against COVID-19 variants

SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions.

29 May 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.

22 May 2024